Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Stempeutics Cleared To Test Nation’s Stem Cell-Based Drugs

This article was originally published in PharmAsia News

Executive Summary

India's drug regulators have cleared another company to conduct clinical trials, this one specializing on use of drugs that are based on stem cells for treating heart problems. The Drug Controller General Of India approved Stempeutics Research to become the nation's first firm to conduct trials of stem cell-based drugs. Stempeutics plans to focus on adult stem cells in mesenchymal derived from bone marrow as it invests heavily in attempting to develop new products. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel